Baird Upgrades Sarepta Therapeutic (SRPT) to Outperform; Favorable Risk/Reward

May 6, 2015 6:10 AM

Baird upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Outperform with a price target of $20.00 (from $16.00), citing favorable ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found